Results of a global network database of patients with type 2 diabetes suggest that sodium-glucose cotransporter-2 inhibitors could reduce the incident risk for gastrointestinal cancers except pancreatic cancer. In a comparison of SGLT2 and dipeptidyl peptidase-4 inhibitors, patients started on SGLT2 inhibitors had almost a 15% lower risk for these malignancies.
The study showed protection against cancers of the colon, esophagus, stomach, small intestine, rectosigmoid junction, rectum, anus,